A selective, slow binding inhibitor of factor VIIa binds to a nonstandard active site conformation and attenuates thrombus formation in vivo.
Olivero, A.G., Eigenbrot, C., Goldsmith, R., Robarge, K., Artis, D.R., Flygare, J., Rawson, T., Sutherlin, D.P., Kadkhodayan, S., Beresini, M., Elliott, L.O., DeGuzman, G.G., Banner, D.W., Ultsch, M., Marzec, U., Hanson, S.R., Refino, C., Bunting, S., Kirchhofer, D.(2005) J Biol Chem 280: 9160-9169
- PubMed: 15632123 
- DOI: 10.1074/jbc.M409068200
- Primary Citation of Related Structures:  
1YGC - PubMed Abstract: 
The serine protease factor VIIa (FVIIa) in complex with its cellular cofactor tissue factor (TF) initiates the blood coagulation reactions. TF.FVIIa is also implicated in thrombosis-related disorders and constitutes an appealing therapeutic target for treatment of cardiovascular diseases ...